A Study Of GLP-1 Receptor Agonist-Induced Weight Loss On Airway Hyperresponsiveness
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 26-011174
About this study
The purpose of this study is to determine whether GLP-1 receptor agonist therapy can reduce airway hyperresponsiveness in patients with obesity and evidence of airway hyperresponsiveness and asthma
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
≥18 years of age
BMI ≥30 kg/m²
Physician-diagnosed asthma, objectively confirmed with positive methacholine challenge at baseline screening
Stable asthma therapy for ≥1 month prior to screening
Access to GLP-1 RA therapy for 6 months
Active Mayo Clinic Medical Record Number
Ability to provide informed consent
Exclusion Criteria:
Use of obesity medication within last 3 months
Unintentional weight loss ≥ 20 lbs within last 3 months
Current smoking/vaping of tobacco or cannabis within last 3 months
History of bariatric surgery within last year
Diagnosis of other chronic pulmonary condition (i.e. lung cancer, ILD)
Systemic corticosteroid use within the past 3 months
Known or suspected allergy to GLP-1 RA
Contraindication to GLP-1 RA therapy
Participation in another clinical trial involving an investigational product
Pregnant, breastfeeding, intending to become pregnant during study period
Any condition that in the opinion of the investigator would interfere with participation, confound interpretation of results, or pose undue risk
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 09/16/2026. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Jacksonville, Fla.
Mayo Clinic principal investigator Leah Ishmael, D.O. |
Open for enrollment |
|
More information
Publications
Publications are currently not available